TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34432828

Group type: EXPERIMENTAL
Intervention: Higher socioeconomic status (SES)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Higher income
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Higher SES indicators (car ownership)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Higher SES indicators (television ownership)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Higher SES indicators (electricity access)
Number of subjects: 279

Group type: COMPARATOR
Intervention: No education
Number of subjects: 279

Group type: COMPARATOR
Intervention: Lower income
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Water kiosk use
Number of subjects: 279
Study: 34432850

Group type: EXPERIMENTAL
Intervention: 6-month complex lifestyle intervention (two 1-hour group sessions per week with instructor-led exercise and three 2-hour group counselling sessions)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 6-month complex lifestyle intervention
Number of subjects: 16
Study: 34432863

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 258
Study: 34432870

Group type: EXPERIMENTAL
Intervention: m-EASIX (modified EASIX)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: m-EASIX
Number of subjects: 118

Group type: COMPARATOR
Intervention: m-EASIX, simplified EASIX, EASIX
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Low PLTs and high CRP
Number of subjects: 118
Study: 34432869

Group type: EXPERIMENTAL
Intervention: Tolerance conditioning regimen (total lymphoid irradiation, anti-thymocyte globulin conditioning, donor hematopoietic cell transplant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posttransplant pmn MDSCs
Number of subjects: 0
Study: 34432874

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS) based monitoring of circulating tumor DNA (ctDNA)
Number of subjects: 45
Study: 34433298

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 75
Study: 34433304

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic prostatectomy (RALP)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Open radical prostatectomy (ORP)
Number of subjects: 1094
Study: 34433303

Group type: EXPERIMENTAL
Intervention: UGN-102 (6 once-weekly instillations)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: UGN-102
Number of subjects: 63
Study: 34433309

Group type: EXPERIMENTAL
Intervention: First-pass effect (FPE) achieved in 93 patients (33.2%)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: First-pass effect (FPE)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Contact aspiration as first-line strategy
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Baseline antiplatelets and atheromatous etiology
Number of subjects: 280
Study: 34433344

Group type: EXPERIMENTAL
Intervention: Low to moderate CCI with MCC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High CCI with MCC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High CCI and metastatic cancer
Number of subjects: 0
Study: 34433359

Group type: EXPERIMENTAL
Intervention: SitLess with MS intervention
Number of subjects: 41
Study: 34433476

Group type: EXPERIMENTAL
Intervention: Physical activity guidelines at 1 year of age
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Sleeping for 11-14 hours or having consistent wake and sleep times at 1 year of age
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Screen time guidelines at 5 years of age
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Adherence to all three guidelines at 1 year of age
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Adherence to all three guidelines at 5 years of age
Number of subjects: 528
Study: 34433481

Group type: EXPERIMENTAL
Intervention: NfL-based prediction model
Number of subjects: 125

Group type: COMPARATOR
Intervention: Lead-in approach
Number of subjects: 125

Group type: COMPARATOR
Intervention: ΔFRS-based approach
Number of subjects: 125
Study: 34433549

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant 0.7 mg (DEX; Ozurdex)
Number of subjects: 57
Study: 34433593

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural treatment for childhood insomnia (CBT-CI) adapted for children with ASD (in-person or remote)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sleep Hygiene and Related Education
Number of subjects: 180

Group type: COMPARATOR
Intervention: CBT-CI and Sleep Hygiene Education
Number of subjects: 180
Study: 34433608

Group type: EXPERIMENTAL
Intervention: 12-month dietary intervention delivered via face-to-face motivational interviews, fortnightly motivational phone calls, monthly electronic pamphlets, quarterly newsletters and quarterly group meetings.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 12-month dietary intervention
Number of subjects: 55
Study: 34433633

Group type: EXPERIMENTAL
Intervention: WT1-sensitized T cells dosed at 5×10
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: WT1-sensitized T cells
Number of subjects: 12
Study: 34433649

Group type: EXPERIMENTAL
Intervention: Tafasitamab + Lenalidomide
Number of subjects: 76

Group type: COMPARATOR
Intervention: Lenalidomide Monotherapy
Number of subjects: 76
Study: 34433648

Group type: EXPERIMENTAL
Intervention: LSZ102 alone (arm A)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: LSZ102 with ribociclib (arm B)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: LSZ102 with alpelisib (arm C)
Number of subjects: 198
Study: 34433780

Group type: EXPERIMENTAL
Intervention: AI-assisted automatic cataract grading program based on LOCS III
Number of subjects: 0
Study: 34434256

Group type: EXPERIMENTAL
Intervention: 4F-FPS (Flow diversion Predictive Score)
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Derivation group
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Validation group
Number of subjects: 662
Study: 34434565

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (34 Gy/10#/2 weeks + 10 Gy/5#/1 wk for BCS patients)
Number of subjects: 50
Study: 34435165

Group type: EXPERIMENTAL
Intervention: Gum-chewing added to conventional postoperative feeding regimen
Number of subjects: 0
Study: 34435395

Group type: EXPERIMENTAL
Intervention: BEO (bergamot essential oil) cream (80 mg) applied trans-dermally twice a day for 4 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo cream applied trans-dermally twice a day for 4 weeks
Number of subjects: 134
Study: 34435403

Group type: EXPERIMENTAL
Intervention: High adherence to integrative oncology (AIC)
Number of subjects: 439
Study: 34435432

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34435552

Group type: EXPERIMENTAL
Intervention: Early PET/CT scans on days 4 (D4) and 21 (D21) of cycle 1 (C1) of salvage therapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Early PET/CT response at D4 or D21
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Persistent response on both D4 and D21
Number of subjects: 25
Study: 34435684

Group type: EXPERIMENTAL
Intervention: Oral alisertib 45 to 100 mg/m²
Number of subjects: 0
Study: 34435699

Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 34435897

Group type: EXPERIMENTAL
Intervention: Pregnancy and lactation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical treatments affecting bone metabolism
Number of subjects: 0
Study: 34435960

Group type: EXPERIMENTAL
Intervention: Previsit patient important issue questionnaire
Number of subjects: 34037

Group type: EXPERIMENTAL
Intervention: EHR tools for patient engagement
Number of subjects: 34037
Study: 34435962

Group type: EXPERIMENTAL
Intervention: OTS mat condition (seated players)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Adapted mat condition
Number of subjects: 78

Group type: COMPARATOR
Intervention: OTS mat condition (standing players)
Number of subjects: 78
Study: 34435968

Group type: EXPERIMENTAL
Intervention: Medimoov exergame platform
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard psychomotor rehabilitation
Number of subjects: 50
Study: 34435971

Group type: EXPERIMENTAL
Intervention: Website-only intervention
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Website-coaching intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study: 34436569

Group type: EXPERIMENTAL
Intervention: ABX464 (150 mg daily for 4 weeks)
Number of subjects: 9
Study: 34437304

Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy (DR)
Number of subjects: 87

Group type: COMPARATOR
Intervention: No DR
Number of subjects: 87
Study: 34437720

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34438022

Group type: EXPERIMENTAL
Intervention: Parent-reported irritability
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Child-reported anger
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Aggression
Number of subjects: 195
Study: 34438254

Group type: EXPERIMENTAL
Intervention: Dynamic Inference Task (DIT) with high nonemotional inference
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dynamic Inference Task (DIT) with emotional presence in high-inference condition
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dynamic Inference Task (DIT) with low inference
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dynamic Inference Task (DIT) with nonemotional presence
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dynamic Inference Task (DIT) with direct gaze
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dynamic Inference Task (DIT) with averted gaze
Number of subjects: 51
Study: 34438333

Group type: EXPERIMENTAL
Intervention: Paretic leg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-paretic leg
Number of subjects: 42
Study: 34438449

Group type: EXPERIMENTAL
Intervention: AED delivery by drones
Number of subjects: 14

Group type: COMPARATOR
Intervention: Test flights of AED delivery by drones
Number of subjects: 14
Study: 34438469

Group type: COMPARATOR
Intervention: Low-dose colchicine
Number of subjects: 803

Group type: COMPARATOR
Intervention: High-dose colchicine
Number of subjects: 803
Study: 34438804

Group type: EXPERIMENTAL
Intervention: Pet ownership
Number of subjects: 162

Group type: COMPARATOR
Intervention: No pet ownership (control)
Number of subjects: 162
Study: 34439146

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) delivered as planned (60Gy in 15 fractions of 4.0Gy)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 6
Study: 34439152

Group type: EXPERIMENTAL
Intervention: Euclidean distance (Euc)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Manhattan distance (Man)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Tchebychev distance (Tch)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Travelling Salesman Problem distance (TSP)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: High SDmax
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: High SD_TSP
Number of subjects: 290
Study: 34439167

Group type: EXPERIMENTAL
Intervention: Fasting-Mimicking Diet (FMD) administered every three weeks/once a month, average of 6.3 cycles/patient
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fasting-Mimicking Diet (FMD)
Number of subjects: 90
Study: 34439258

Group type: EXPERIMENTAL
Intervention: DEEPGENTM platform for cancer detection
Number of subjects: 675

Group type: COMPARATOR
Intervention: Control group (individuals with no known malignancy)
Number of subjects: 675
Study: 34439284

Group type: EXPERIMENTAL
Intervention: zPDX (zebrafish patient-derived xenograft) exposed to chemotherapy regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Responder group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Responder group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 34439518

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) 40-60 mg/Kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34440175

Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Complete switch-off of cancer lesions and cardiac lighting
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Multivariate Cox regression analysis
Number of subjects: 86
Study: 34440684

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined HIIT with strength training (COM)
Number of subjects: 13
Study: 34440710

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine
Number of subjects: 283
Study: 34441766

Group type: EXPERIMENTAL
Intervention: PCOS girls
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (without PCOS)
Number of subjects: 96
Study: 34441840

Group type: EXPERIMENTAL
Intervention: Ciclesonide (320 µg inhalation twice per day for 14 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 61
Study: 34442202

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT) sessions of 10,000 lux for 30 minutes, Monday through Friday, for 4 weeks.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 100
Study: 34442403

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study: 34442445

Group type: EXPERIMENTAL
Intervention: Laser Doppler Flowmetry (LDF) applied to traumatised teeth
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (sound and healthy teeth)
Number of subjects: 44
Study: 34444128

Group type: EXPERIMENTAL
Intervention: Night shift work
Number of subjects: 59

Group type: COMPARATOR
Intervention: Day shift work
Number of subjects: 59
Study: 34445916

Group type: EXPERIMENTAL
Intervention: pegcetacoplan
Number of subjects: 263

Group type: COMPARATOR
Intervention: ravulizumab
Number of subjects: 263
Study: 34446008

Group type: EXPERIMENTAL
Intervention: Public transport use (≥3 days/week)
Number of subjects: 8547

Group type: EXPERIMENTAL
Intervention: Public transport use (≥6 days/week)
Number of subjects: 8547

Group type: COMPARATOR
Intervention: Private transport mode
Number of subjects: 8547

Group type: COMPARATOR
Intervention: Private transport use (≥6 days/week)
Number of subjects: 8547

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 8547

Group type: EXPERIMENTAL
Intervention: Mixed and other ethnicity (Asian, Indigenous, Gypsy, and other)
Number of subjects: 8547

Group type: EXPERIMENTAL
Intervention: High socioeconomic level and middle/high education level
Number of subjects: 8547
Study: 34446044

Group type: EXPERIMENTAL
Intervention: Surgical treatment for colorectal cancer
Number of subjects: 0
Study: 34446089

Group type: EXPERIMENTAL
Intervention: Sympathetic amplitude response
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sympathetic responses
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Parasympathetic responses
Number of subjects: 21
Study: 34446110

Group type: EXPERIMENTAL
Intervention: CPAP/O
Number of subjects: 0
Study: 34446224

Group type: EXPERIMENTAL
Intervention: Intraoperative renal desaturation (detected in 38 infants)
Number of subjects: 242

Group type: COMPARATOR
Intervention: No intraoperative renal desaturation (matched group of 114 infants)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Cumulative time of renal desaturation
Number of subjects: 242
Study: 34446358

Group type: EXPERIMENTAL
Intervention: Real-time PCR with polyadenylic acid (poly[A])
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real-time PCR without poly(A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real-time PCR tests performed on different days
Number of subjects: 0
Study: 34446377

Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (OEP)
Number of subjects: 30
Study: 34446378

Group type: EXPERIMENTAL
Intervention: Non-surgical patients
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: American Association of Anesthesiologists class
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Impaired daily functioning
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Dependent living
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Major postoperative complication in surgical patients
Number of subjects: 273
Study: 34446577

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy
Number of subjects: 46
Study: 34446679

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiation
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Follow-up for ≥12 months
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Causes of death
Number of subjects: 1177

Group type: EXPERIMENTAL
Intervention: Deaths among CrAg-positive individuals
Number of subjects: 1177
Study: 34446728

Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 73
Study: 34446764

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 1742
Study: 34447323

Group type: EXPERIMENTAL
Intervention: Unilateral Transcranial Photobiomodulation
Number of subjects: 0
Study: 34448184

Group type: EXPERIMENTAL
Intervention: Protein signature for PDAC screening
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Protein signature score (PSS) combined with patient age
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: PSS
Number of subjects: 58
Study: 34448185

Group type: EXPERIMENTAL
Intervention: Location-based resect-and-discard strategy
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Optical diagnosis using NICE classification
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Optical diagnosis using Sano classification
Number of subjects: 1117
Study: 34448598

Group type: EXPERIMENTAL
Intervention: FGF21 level measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kidney glucose uptake measurement
Number of subjects: 0
Study: 34448665

Group type: EXPERIMENTAL
Intervention: Mobile application for self-management of IBD patients
Number of subjects: 55
Study: 34448679

Group type: EXPERIMENTAL
Intervention: MRI visual T-category
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: VI-RADS score
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both subjective MRI visual T-category and VI-RADS score
Number of subjects: 45
Study: 34448726

Group type: EXPERIMENTAL
Intervention: EQ VAS (Visual Analog Scale)
Number of subjects: 700000

Group type: EXPERIMENTAL
Intervention: EQ-5D dimensions
Number of subjects: 700000

Group type: EXPERIMENTAL
Intervention: Self-assessed EQ VAS values
Number of subjects: 700000

Group type: COMPARATOR
Intervention: General population VAS and time trade-off value sets
Number of subjects: 700000
Study: 34448728

Group type: EXPERIMENTAL
Intervention: Observation and correction of inhaler technique using device-specific checklists for 13 inhaler types.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Use of an identical placebo device for observing inhaler technique.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Technique optimization or switching to a suitable inhaler.
Number of subjects: 0
Study: 34448755

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Pain Education (EDU)
Number of subjects: 168
Study: 34448816

Group type: EXPERIMENTAL
Intervention: Dynamic Time-Warped Pearson Correlations (DTW-PC)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pearson Correlations (PC)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) classification
Number of subjects: 81
Study: 34448930

Group type: EXPERIMENTAL
Intervention: New-onset neurological symptoms (NNS)
Number of subjects: 10881
Study: 34449252

Group type: EXPERIMENTAL
Intervention: Body Image After Mastectomy Scale
Number of subjects: 0
Study: 34449258

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34449262

Group type: EXPERIMENTAL
Intervention: Head-Mounted Display Virtual Reality Games
Number of subjects: 0
Study: 34449807

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Total physical activity (PA)
Number of subjects: 503
Study: 34449877

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg intravenously
Number of subjects: 151
Study: 34449941

Group type: EXPERIMENTAL
Intervention: Supportive Care (SC) needs assessment using SCNS-SF34 before radical cystectomy and at 1, 3, 6, and 12 months post-surgery.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Utilization of SC services and willingness to use SC services.
Number of subjects: 90
Study: 34451560

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34452642

Group type: EXPERIMENTAL
Intervention: COPESS plus treatment as usual (TAU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 60
Study: 34452981

Group type: EXPERIMENTAL
Intervention: Integrated Community-Based Health Systems-Strengthening (ICBHSS) initiative
Number of subjects: 10022
Study: 34453044

Group type: EXPERIMENTAL
Intervention: Pembrolizumab and entinostat
Number of subjects: 29
Study: 34453203

Group type: EXPERIMENTAL
Intervention: ODAP-Urea-based ligands
Number of subjects: 0
Study: 34453241

Group type: EXPERIMENTAL
Intervention: Lurbinectedin and cisplatin combination with aprepitant (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurbinectedin and cisplatin combination without aprepitant (Group B)
Number of subjects: 0
Study: 34453519

Group type: EXPERIMENTAL
Intervention: HIV-positive donors
Number of subjects: 92
Study: 34453569

Group type: EXPERIMENTAL
Intervention: Health awareness
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Body change concerns
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Life interferences
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Worry
Number of subjects: 229
Study: 34453622

Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography (EIT) with saline bolus (10 ml 10% NaCl injection) during a respiratory hold
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (15 patients without ARF)
Number of subjects: 108
Study: 34453682

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 203
Study: 34454047

Group type: EXPERIMENTAL
Intervention: Frameless unilateral radiosurgical ablation of the thalamic ventral intermediate nucleus to a maximum dose of 160 Gy
Number of subjects: 33